Plaque Psoriasis

David Oberlin, MD, explains why APEX's enriched trial population, not drug mechanism, likely drove its unique radiographic success in psoriatic arthritis.

Phase 3 data show zasocitinib use led to clear or almost clear skin in around 70% of patients by Week 16, setting up an FDA decision in early 2027.

A roundup of dermatology's biggest August headlines, from an FDA approval to conference previews and conversations on equity in care.

At Week 52, ixekizumab plus tirzepatide sustained gains in skin clearance, joint response and metabolic measures versus ixekizumab alone.

Baseline structural damage accounted for most of the variance in placebo-arm radiographic progression across 6 PsA trials.

Saakshi Khattri, MD, discusses mental health screening gaps in psoriasis and a new Th17/type 2 immune signature study pointing toward personalized care.

Saakshi Khattri, MD, discusses oral TYK2 inhibitor and IL-23 antagonist data alongside weight-loss combination therapy reshaping psoriasis and PsA care.

Sonelokimab hit its primary ACR50 end point and all key secondary end points in biologic-naive patients with psoriatic arthritis in the phase 3 IZAR-1 trial.

Oral socrodeucitinib 12 mg significantly improved PASI 75 and sPGA responses versus placebo at Week 12 in a 125-patient phase 2 trial.

Catch up on July dermatology news: vitiligo and alopecia data, a pipeline discontinuation, psoriasis comparisons, and an FDA sNDA acceptance.

This Q&A highlights the significance of the FDA approval of risankizumab (Skyrizi) for psoriasis and psoriatic arthritis in pediatric patients.

New secondary endpoint analyses from Phase 3 LATITUDE PsO 3001 and 3002 reveal high rates of clearance on high-impact areas.

During her SDPA Conference interview, Murase gave several more tips for skin management during pregnancy.

This review highlights some of the most notable stories covered by the HCPLive team within the first half of 2026.

This review highlights the most notable dermatology news stories covered by HCPLive during the second quarter of 2026.

This new analysis indirectly compares the clinical efficacy of risankizumab and icotrokinra in adults living with moderate-to-severe plaque psoriasis.

This review of June 2026 headlines covers the most notable stories in dermatology, including FDA news, new data, and podcast updates.

FDA approves steroid-free roflumilast cream for plaque psoriasis in children age 2+, bringing once-daily option for sensitive areas.

FDA approved risankizumab for children aged 6 years or older with plaque psoriasis or active psoriatic arthritis.

Dawn Eichenfield, MD, PhD, discusses differential diagnosis, off-label treatment rationale, and multidisciplinary care for rare and atypical skin conditions in children.

DiRuggiero on PsO-LD, a heating pad for molluscum, and why psoriasis counseling must now include pulmonary risk.

This discussion of integrative dermatology highlights ways to combine conventional medicine and complementary or alternative medicine.

LATITUDE Atlas saw more than 35% of patients receiving zasocitinib 30 mg once daily reaching a PASI100 response at week 16, the primary endpoint.

This preview of the 2026 SDPA Summer Dermatology Conference highlights different sessions and interviews covered by the HCPLive team.

This installment of our Month in Review series highlights top news headlines and podcast updates in dermatology from May 2026.